- 
MRNA had one of the worst year in 2024. However, cash position is underestimated and the market cap has gotten very low for a company which has proven it's excellence in manufacturing drug and research.
-MRNA is working on cancer prevention vaccines which might get approvals in 2026 which will be a huge propeller for the stock long term.
- In the short term 2025, Bird flue and HMPV in China should push the stock higher to it's fair value around $65-90 range before end of the year.
- Wall street & Media pundits are saying nothing to worry about. But it's better to front run on these type of situations if you want to score big gains.
MRNA had one of the worst year in 2024. However, cash position is underestimated and the market cap has gotten very low for a company which has proven it's excellence in manufacturing drug and research. -
MRNA is working on cancer prevention vaccines which might get approvals in 2026 which will be a huge propeller for the stock long term. - In the short term 2025, Bird flue and HMPV in China should push the stock higher to it's fair value around $65-90 range before end of the year.
- Wall street & Media pundits are saying nothing to worry about. But it's better to front run on these type of situations if you want to score big gains.
交易結束：達到停損點
Huge damage done to this chart after that gap down of 20%+ on Jan 13, 2024 after minutes of JP morgan healthcare summit. Seems like Moderna wants to go lower and find a bottom. Closing the trade and using it in other plays than waiting & holding as thesis is voided.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。